JP2002523517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002523517A5 JP2002523517A5 JP2000567559A JP2000567559A JP2002523517A5 JP 2002523517 A5 JP2002523517 A5 JP 2002523517A5 JP 2000567559 A JP2000567559 A JP 2000567559A JP 2000567559 A JP2000567559 A JP 2000567559A JP 2002523517 A5 JP2002523517 A5 JP 2002523517A5
- Authority
- JP
- Japan
- Prior art keywords
- peptides
- helix
- peptide
- amino acids
- bulky
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000001472 cytotoxic effect Effects 0.000 description 10
- 125000002091 cationic group Chemical group 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9818938.4 | 1998-08-28 | ||
| GBGB9818938.4A GB9818938D0 (en) | 1998-08-28 | 1998-08-28 | Bioactive peptides |
| PCT/GB1999/002850 WO2000012541A2 (en) | 1998-08-28 | 1999-08-31 | Cytotoxic peptides modified by bulky or lipophilic moieties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002523517A JP2002523517A (ja) | 2002-07-30 |
| JP2002523517A5 true JP2002523517A5 (https=) | 2010-10-07 |
| JP5475937B2 JP5475937B2 (ja) | 2014-04-16 |
Family
ID=10838089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000567559A Expired - Fee Related JP5475937B2 (ja) | 1998-08-28 | 1999-08-31 | 生物活性ペプチド |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6890902B2 (https=) |
| EP (2) | EP1109827B1 (https=) |
| JP (1) | JP5475937B2 (https=) |
| AT (2) | ATE513847T1 (https=) |
| AU (2) | AU5526899A (https=) |
| CA (2) | CA2340326A1 (https=) |
| DE (1) | DE69943130D1 (https=) |
| DK (1) | DK1109831T3 (https=) |
| ES (1) | ES2359616T3 (https=) |
| GB (1) | GB9818938D0 (https=) |
| NO (1) | NO333073B1 (https=) |
| WO (2) | WO2000012541A2 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0605685D0 (en) * | 2006-03-21 | 2006-05-03 | Lytix Biopharma As | Inhibition of tumour growth |
| US8283315B2 (en) | 1998-08-28 | 2012-10-09 | Lytix Biopharma As | Inhibition of tumour growth |
| GB9818938D0 (en) | 1998-08-28 | 1998-10-21 | Alpharma As | Bioactive peptides |
| US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
| GB0005702D0 (en) * | 2000-03-09 | 2000-05-03 | Alpharma As | Method |
| GB0005703D0 (en) | 2000-03-09 | 2000-05-03 | Alpharma As | Compounds |
| KR20020080731A (ko) * | 2001-04-17 | 2002-10-26 | 주식회사 이지바이오 시스템 | 락토페리신 유전자 및 이를 도입한 락토페리신 발현용형질전환체 |
| KR100454595B1 (ko) * | 2001-11-30 | 2004-10-28 | 주식회사 이지바이오 시스템 | 락토페리신 유전자 및 이를 도입한 형질전환 대장균 |
| SE0200598D0 (sv) * | 2002-02-27 | 2002-02-27 | A & Science Invest Ab | Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences |
| CN100467059C (zh) | 2002-05-10 | 2009-03-11 | 阿根尼克斯有限公司 | 乳铁蛋白在治疗恶性肿瘤疾病中的用途 |
| CA2490290A1 (en) * | 2002-06-28 | 2004-01-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins |
| NO20031818D0 (no) * | 2003-04-23 | 2003-04-23 | Uni I Tromsoe | Fremgangsmåte av bioaktiv peptid forberedelse |
| US8105615B2 (en) * | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| CA2533753C (en) * | 2004-03-19 | 2012-10-16 | Morinaga Milk Industry Co., Ltd. | Drug for cancer therapy |
| US8202841B2 (en) * | 2004-06-17 | 2012-06-19 | Mannkind Corporation | SSX-2 peptide analogs |
| US8034762B2 (en) * | 2004-09-02 | 2011-10-11 | Cognosci, Inc. | Treatment of subarachnoid hemorrhage with Apo E analogs |
| WO2006047744A2 (en) * | 2004-10-26 | 2006-05-04 | Agennix Incorporated | Compositions of lactoferrin related peptides and uses thereof |
| WO2006054908A1 (en) * | 2004-11-19 | 2006-05-26 | Fonterra Corporate Research And Development Limited | Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer |
| DE102005051366A1 (de) * | 2005-10-25 | 2007-04-26 | Degussa Gmbh | Drug Delivery Systeme |
| WO2007055578A1 (en) * | 2005-11-11 | 2007-05-18 | Leids Universitair Medisch Centrum | Cyclic antimicrobial peptides derived from lactoferrin |
| PL1966240T6 (pl) | 2005-12-30 | 2012-05-31 | Evonik Roehm Gmbh | Peptydy laktoferyny użyteczne jako peptydy penetrujące komórkę |
| ES2321358B1 (es) * | 2006-04-05 | 2010-03-05 | Consejo Susperior De Investigaciones Cientificas | Uso de peptidos derivados de la lactoferrina para preparar formulaciones inhibidoras de la enzima conversora de angiotensina i. |
| JP2009535027A (ja) * | 2006-04-27 | 2009-10-01 | シンガポール ヘルス サービシーズ ピーティーイー リミテッド | 抗菌ペプチド |
| US7960339B2 (en) | 2006-07-10 | 2011-06-14 | Österreichische Akademie der Wissenschaften | Antimicrobial peptides |
| GB0821616D0 (en) | 2008-11-26 | 2008-12-31 | Lytix Biopharma As | Compounds |
| EP2754450A1 (en) * | 2013-01-11 | 2014-07-16 | Österreichische Akademie der Wissenschaften | Lactoferricin derived peptides |
| GB201401877D0 (en) | 2014-02-04 | 2014-03-19 | Univ Tromsoe | Peptides |
| CN106794218A (zh) * | 2014-10-08 | 2017-05-31 | 学校法人庆应义塾 | 白细胞的细胞外诱捕网形成抑制剂 |
| ITUB20153058A1 (it) * | 2015-08-11 | 2017-02-11 | Farmagens Health Care S R L Roma | ?frammento di lattoferrina per uso come agente antibatterico ed antivirale? |
| US11213512B2 (en) | 2016-06-21 | 2022-01-04 | The Curators Of The University Of Missouri | Bis-amino acid based compound and use thereof |
| US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
| US11364275B2 (en) | 2017-08-04 | 2022-06-21 | Bioventures, Llc | Linear lipopeptide paenipeptins and methods of using the same |
| US11236138B2 (en) * | 2020-01-14 | 2022-02-01 | Renorigin Innovation Institute Co., Ltd. | Peptide, method and composition for melanin polymerization and hair darkening |
| CN115073352A (zh) * | 2022-06-28 | 2022-09-20 | 吉尔多肽生物制药(大连市)有限公司 | 一种2,5,7-三叔丁基色氨酸的合成方法 |
| CN121086066A (zh) * | 2024-12-19 | 2025-12-09 | 合肥工业大学 | 牛乳铁蛋白多肽及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141581A (en) * | 1972-10-08 | 1992-08-25 | Markham Harold A | Implants with a cover which resists formation of firm spherical encapsulation |
| US4476116A (en) * | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US5073542A (en) | 1989-06-07 | 1991-12-17 | Magainin Sciences Inc. | CPF peptide compositions and their use in inhibiting growth of target cells or a virus |
| DK167813B1 (da) | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
| US5141851A (en) * | 1990-04-18 | 1992-08-25 | Board Of Regents, The University Of Texas System | Isolated farnesyl protein transferase enzyme |
| JP2818056B2 (ja) * | 1990-09-07 | 1998-10-30 | 森永乳業株式会社 | 抗菌性ペプチドおよび抗菌剤 |
| NZ241936A (en) * | 1991-03-13 | 1994-03-25 | Morinaga Milk Industry Co Ltd | Antimicrobial peptide and its use in an antimicrobial composition |
| CA2111214A1 (en) * | 1991-06-12 | 1992-12-23 | W. Lee Maloy | Composition and treatment with biologically active peptides having c-terminal substitutions |
| US5547939A (en) * | 1991-06-14 | 1996-08-20 | The Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
| US5646119A (en) * | 1991-11-01 | 1997-07-08 | Periodontix, Inc. | D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents |
| US5631228A (en) * | 1991-11-01 | 1997-05-20 | Periodontix, Inc. | Anti-fungal and anti-bacterial histatin-based peptides |
| DK0629347T3 (da) | 1992-01-23 | 1998-02-16 | Morinaga Milk Industry Co Ltd | Antibakterielt middel og behandling af genstande dermed |
| EP0644769A4 (en) * | 1992-06-01 | 1995-08-09 | Magainin Pharma | BIOLOGICALLY ACTIVE PEPTIDES WITH N-TERMINAL SUBSTITUTIONS. |
| AU673190B2 (en) * | 1992-07-13 | 1996-10-31 | Bionebraska, Inc. | Method for modification of recombinant polypeptides |
| US5593866A (en) | 1992-08-21 | 1997-01-14 | The University Of British Columbia | Cationic peptides and method for production |
| WO1994012206A1 (en) | 1992-12-03 | 1994-06-09 | Magainin Pharmaceuticals, Inc. | Treatment of dermatological malignancies with biologically active peptides |
| JP3312946B2 (ja) * | 1993-03-04 | 2002-08-12 | 雪印乳業株式会社 | ウイルス感染・増殖抑制剤 |
| US5789542A (en) * | 1994-04-22 | 1998-08-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Amphipathic peptides |
| WO1998006425A1 (en) * | 1996-08-12 | 1998-02-19 | A+ Science Invest Ab | Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin |
| CA2262429A1 (en) * | 1996-08-14 | 1998-02-19 | Novartis Ag | Peptide with inhibitory activity towards plant pathogenic fungi |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| WO1998040091A1 (en) * | 1997-03-13 | 1998-09-17 | The Research Foundation Of State University Of New York | Microbicidal peptides and methods of use |
| GB9818938D0 (en) | 1998-08-28 | 1998-10-21 | Alpharma As | Bioactive peptides |
-
1998
- 1998-08-28 GB GBGB9818938.4A patent/GB9818938D0/en not_active Ceased
-
1999
- 1999-08-31 WO PCT/GB1999/002850 patent/WO2000012541A2/en not_active Ceased
- 1999-08-31 WO PCT/GB1999/002851 patent/WO2000012542A2/en not_active Ceased
- 1999-08-31 CA CA002340326A patent/CA2340326A1/en not_active Abandoned
- 1999-08-31 AT AT99941774T patent/ATE513847T1/de not_active IP Right Cessation
- 1999-08-31 DK DK99941773.6T patent/DK1109831T3/da active
- 1999-08-31 EP EP99941774A patent/EP1109827B1/en not_active Expired - Lifetime
- 1999-08-31 AT AT99941773T patent/ATE495192T1/de active
- 1999-08-31 AU AU55268/99A patent/AU5526899A/en not_active Abandoned
- 1999-08-31 CA CA2341037A patent/CA2341037C/en not_active Expired - Fee Related
- 1999-08-31 EP EP99941773A patent/EP1109831B1/en not_active Expired - Lifetime
- 1999-08-31 JP JP2000567559A patent/JP5475937B2/ja not_active Expired - Fee Related
- 1999-08-31 ES ES99941773T patent/ES2359616T3/es not_active Expired - Lifetime
- 1999-08-31 AU AU55267/99A patent/AU772176B2/en not_active Ceased
- 1999-08-31 DE DE69943130T patent/DE69943130D1/de not_active Expired - Lifetime
-
2001
- 2001-02-27 US US09/798,869 patent/US6890902B2/en not_active Expired - Fee Related
- 2001-02-27 NO NO20010995A patent/NO333073B1/no not_active IP Right Cessation
- 2001-02-27 US US09/798,026 patent/US7439228B2/en not_active Expired - Fee Related
-
2008
- 2008-07-02 US US12/217,160 patent/US8143211B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002523517A5 (https=) | ||
| Semreen et al. | Recent updates of marine antimicrobial peptides | |
| JP5688290B2 (ja) | 抗菌性ペプチド | |
| Dennison et al. | Amphiphilic α-helical antimicrobial peptides and their structure/function relationships | |
| JP3147904B2 (ja) | 広域スペクトル抗菌化合物と使用方法 | |
| JP5475937B2 (ja) | 生物活性ペプチド | |
| Haug et al. | The medicinal chemistry of short lactoferricin-based antibacterial peptides | |
| Shai et al. | Host defense peptides and lipopeptides: modes of action and potential candidates for the treatment of bacterial and fungal infections | |
| US9352015B2 (en) | Antimicrobial peptides | |
| US20020077298A1 (en) | Anti-fungal peptides | |
| CN1650005B (zh) | 抗菌性多肽及其应用 | |
| CN101111256A (zh) | 抗菌肽及其使用方法 | |
| Ryge et al. | New indolicidin analogues with potent antibacterial activity | |
| Shin et al. | Cecropin a‐magainin 2 hybrid peptides having potent antimicrobial activity with low hemolytic effect | |
| Bhattacharjya | NMR structures and interactions of antimicrobial peptides with lipopolysaccharide: Connecting structures to functions | |
| Ifrah et al. | Structure‐activity relationship study of anoplin | |
| Zikou et al. | Design and synthesis of cationic Aib‐containing antimicrobial peptides: conformational and biological studies | |
| Cardoso et al. | Peptides containing d-amino acids and retro-inverso peptides: General applications and special focus on antimicrobial peptides | |
| Nagarajan et al. | Peptide therapeutics versus superbugs: highlight on current research and advancements | |
| Dinh et al. | De Novo Design and Their Antimicrobial Activity of Stapled Amphipathic Helices of Heptapeptides. | |
| Ryge et al. | Novel lysine‐peptoid hybrids with antibacterial properties | |
| El Amri et al. | Plasticins: membrane-damaging peptides with ‘chameleon-like’properties | |
| Won et al. | Activity optimization of an undecapeptide analogue derived from a frog-skin antimicrobial peptide | |
| CA2312191A1 (en) | Threonine-containing protegrins | |
| JPH06511234A (ja) | Ｃ末端置換を有する生物活性ペプチド組成物および治療法 |